# Kangrun Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kangrun-bio

- Industry: Biotechnology
- Headquarters: Changzhou, China
- Website: www.curovax.net
- Latest round: Series C (Jul 6, 2025)
- Investors on record: 6

## About

Founded in 2011 and based in Changzhou, China, Kangrun Bio is a vaccine company integrating R&D, production, and sales. The company boasts comprehensive hardware facilities, including an independent viral vaccine production workshop, R&D laboratory, quality control laboratory, and animal experiment center. In July 2025, Kangrun Bio closed a Series C+ funding from new investors BioTrack Capital, Green Pine Capital Partners, Hangzhou Lula Asset Management, Hankang Capital, Ken Capital and Tigermed.
Kangrun Bio specializes in the development and production of innovative vaccines, including a lyophilized rabies vaccine utilizing Vero cell technology, a quadrivalent influenza virus split vaccine, and several multivalent hand-foot-and-mouth disease vaccines. The company is also advancing several recombinant protein and mRNA vaccines targeting a range of infectious diseases, serving healthcare providers, hospitals, and clinics primarily in China, with plans for expansion into Southeast Asia.
Kangrun Bio generates revenue through direct sales of its vaccines to healthcare institutions and distributors, focusing on bulk sales to hospitals and clinics. Revenue is derived from commercial sales and partnerships with governmental health organizations facilitating vaccination programs.

## Funding rounds

- Series C, Jul 6, 2025 — Green Pine Capital Partners, Hangzhou Lula Asset Management, Ken Capital, BioTrack Capital, Hankang Capital, Tigermed

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series C
- Hangzhou Lula Asset Management (https://capitalatlas.ai/funds/hangzhou-lula-asset-management) — Series C
- Ken Capital (https://capitalatlas.ai/funds/ken-capital) — Series C
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series C
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series C
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series C